Concord Medical Accelerates Global Strategy with a Dual Engine of “Healthcare + AI,” Building a Compassionate and Connected Medical Ecosystem
On February 11, 2026, Concord Medical Group marked a milestone in its global expansion strategy. Group President Jiang Wei and Qian Chaonan, President of Guangzhou Concord Cancer Center, led a core delegation to formally sign a Memorandum of Cooperation with National Hospital Surabaya, the largest comprehensive hospital in Indonesia’s East Java Province, to jointly establish an Integrated Oncology Service Center.
This agreement marks the official launch of Concord Medical Group’s global expansion of its “Healthcare + AI” model. It represents not only a key milestone in the company’s international strategy, but also a significant step forward in showcasing China’s independently developed, high-end medical technologies on the global stage.
Through this partnership, the two sides will jointly build a high-standard oncology care platform in Surabaya, introducing internationally aligned cancer diagnosis and treatment services for local communities. The collaboration is also expected to serve as a replicable “Indonesia model”, offering practical insights into addressing the shortage of oncology medical resources across Southeast Asia.
Cancer has become a major health challenge across Southeast Asia, yet access to advanced medical resources remains severely imbalanced. The shortage of cutting-edge equipment, the lack of standardized oncology care systems, and limited adoption of AI-assisted clinical tools have forced many patients to undertake arduous cross-border journeys in search of treatment.
Against this backdrop, the collaboration led by Concord Medical Group directly addresses these critical gaps. By delivering a systematic, integrated solution, the partnership aims to upgrade regional oncology care standards, offering a sustainable path forward for improving cancer diagnosis and treatment across Southeast Asia.
With years of deep expertise in oncology, Concord Medical Group is bringing to this partnership not a single technology, but a comprehensive, system-level solution—one that is affordable to build, effective to operate, and precise to manage.
• Anchoring Advanced Technologies: From Equipment Export to System Enablement
Concord Medical offers more than cutting-edge modalities such as proton therapy and precision radiotherapy. It delivers a full-spectrum empowerment framework spanning personalized treatment planning, equipment commissioning and optimization, the establishment of clinical quality-control standards, and the implementation of standardized care pathways. Backed by an expert team with a global perspective, this framework ensures that international-standard oncology care is implemented with high fidelity in Indonesia, enabling local patients to access world-class treatment close to home—and putting an end to the burden of cross-border medical travel.
• AI Intelligence as the Catalyst: Breaking Time–Space Barriers and Energizing Local Care
As the defining highlight of the collaboration, the deployment of Concord Medical’s proprietary oncology foundation model and AI-assisted clinical decision systems marks a new phase of intelligent enablement. In the near term, these tools will empower local physicians by significantly improving efficiency and precision, supporting more evidence-based clinical decisions. More profoundly, they will serve as a digital bridge for cross-border medical collaboration, enabling teleconsultations, second opinions, and multidisciplinary team (MDT) discussions. Through this model, Concord Medical’s experts can collaborate in real time with Indonesian clinicians to co-develop optimal treatment plans for complex cases—allowing high-quality medical expertise to transcend geography and reach a far broader population.
The true value of technology and care models ultimately lies in patient benefit. Accordingly, the core of this partnership is not merely technology export, but the joint development of a comprehensive oncology center—a platform designed to build a full-cycle cancer care ecosystem that combines clinical precision with human warmth for Indonesia and the broader Southeast Asian region. Anchored by this vision, the ecosystem aims to shift care from a disease-centered approach to a health-centered one through three key pillars:
• Core Hub: Establishing a Regional Medical Benchmark—Ensuring Access to Care
Built to international top-tier standards, the partnership will co-develop a modern oncology center integrating diagnosis, treatment, and rehabilitation. More than a collection of advanced equipment, it will be a convergence of multidisciplinary expertise—serving as a regional “healing harbor” for patients across Southeast Asia and fundamentally addressing the shortage of high-end oncology services in the region.
• Talent Incubator: Cultivating Local Excellence—Ensuring Sustainable Capability
Through an innovative “sister hospital” model, the collaboration will implement deep personnel exchange programs. Senior clinicians, medical physicists, and nursing leaders will be dispatched to Indonesia for hands-on clinical mentoring and management enablement. The goal is to leave behind a self-sustaining, world-class local team—one that cannot be taken away—ensuring international-standard care takes root and continues to grow locally.
• Lifeline Pathway: Removing Cross-Border Barriers—Bringing Hope Within Reach
An efficient, standardized two-way international referral mechanism will be established. For Indonesian patients requiring proton therapy or other complex precision radiotherapy services, dedicated fast-track pathways will enable seamless access to Guangzhou Taihe Oncology Hospital, ensuring timely connection to global cutting-edge expertise and breaking down geographic barriers that once limited access to life-saving care.
Home to 680 million people, Southeast Asia is experiencing a surge in demand for oncology services amid rising health awareness and accelerating population aging. This opportunity-rich region represents a strategic blue ocean for Concord Medical Group’s global expansion. The partnership with a leading Indonesian hospital marks the Group’s decisive opening move in this blue ocean—signaling the first systematic implementation of its “Healthcare + AI” global strategy.
Building on this new starting point, Concord Medical’s globalization roadmap will advance in three phases:
• Phase One: Establish Regional Footholds
Using Indonesia as a benchmark, the Group will continue to roll out advanced medical technologies and AI systems across more Southeast Asian countries—replicating and localizing the Indonesian model.
• Phase Two: Build a Core Ecosystem
Across target markets, Concord Medical will develop an integrated capability combining medical technology enablement, AI-driven solutions, and cross-border referrals—forming a sustainable ecosystem that serves local patients while connecting to global resources.
• Phase Three: Achieve Shared Value
Through diversified service models, the Group will enhance long-term profitability and reduce operational risk—driving dual growth in commercial value and social impact to support steady, mid- to long-term expansion.
Mr. Jiang Wei, President of Concord Medical Group, commented:
“Healthcare knows no borders, and protecting life is a shared mission for clinicians worldwide. This partnership marks a new beginning for our expansion in Southeast Asia. We are not only exporting technology and services—we are sharing a patient-centered philosophy. Together with our local partners, we aim to build a full-chain oncology ecosystem spanning diagnosis, treatment, rehabilitation, and research, so that more patients can access high-quality, precise, and compassionate cancer care close to home.”
